“…The administration must be modified in patients with renal diseases, adjusting the dosage to the actual renal function. The security in dyalazed patients is limited and the use is not recommended in severe renal failure (creatinine clearance < 30 ml/min) (Abrishami et al, 2010;Della Rocca G et al, 2009;Duvaldestin P et al, 2009;Khuenl-Brady KS et al, 2010;Lee C et al, 2009;McDonagh DL et al, 2011;Plaud B et al, 2009;Schaller SJ et al, 2010;Staals LM et al, 2010;White PF et al,2009) …”